Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ampio Pharmaceuticals and FBM Industria Farmaceutica have entered into a license and distribution agreement providing FMBFarma exclusive rights to market Zertane in Brazil for the treatment of premature ejaculation.
Subscribe to our email newsletter
Financial terms of the agreement have not been disclosed.
FBMFarma will be responsible for obtaining regulatory approval, marketing and distribution in Brazil.
Ampio CEO Michael Macaluso said that FBMFarma was the ideal partner for Ampio in Brazil.
FBM group marketing director Alexandre Ferreira said that HOSPFAR actively sells into both the private and public markets in the country, responding to almost all Brazilian Government tenders.
"FBM group executives are very pleased to establish this partnership with Ampio, since they are extremely confident and enthusiastic about the success that Zertane will have in the Brazilian market," Ferreira added.